HCV is the most common cause of infectious chronic liver disease in western countries [1] . Patients with chronic hepatitis C (CHC) frequently progress to advanced liver fibrosis and cirrhosis, which is associated with high risk of hepatic decompensation and the development of hepatocellular carcinoma [2] . Sustained virological response (SVR) is defined as HCV RNA undetectability 24 weeks after a treatment course of antiviral therapy and correlates with a long-term clinical benefit [3] .
HCV is the most common cause of infectious chronic liver disease in western countries [1] . Patients with chronic hepatitis C (CHC) frequently progress to advanced liver fibrosis and cirrhosis, which is associated with high risk of hepatic decompensation and the development of hepatocellular carcinoma [2] . Sustained virological response (SVR) is defined as HCV RNA undetectability 24 weeks after a treatment course of antiviral therapy and correlates with a long-term clinical benefit [3] .
The current standard of care consisting of pegylated interferon-α (PEG-IFN) and ribavirin leads to SVR rates of 40-50% in patients infected with the HCV genotype 1, which is the most common genotype worldwide [4] . Novel strategies to improve SVR rates include the development of direct antiviral agents such as inhibitors of the HCV non-structural 3/4A (NS3/4A) serine protease [5] . Currently, a multitude of new direct antiviral agents are being assessed in clinical trials [6] . Among them, the clinical development of the NS3/4A protease inhibitors boceprevir and telaprevir is most advanced [7, 8] .
Probably one of the most surprising findings during clinical development of boceprevir and telaprevir was the fact that virological response rates were significantly higher in those individuals randomized to protease inhibitor-based study arms that included PEG-IFN and full-dose ribavirin as compared with PEG-IFN alone or in combination with lower doses of ribavirin. For telaprevir-containing regimens, SVR rates were 60% and 36% in the 12-week PEG-IFN therapy arm with and without ribavirin, respectively [8] . Accordingly, boceprevir-containing regimens showed SVR rates of
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Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir Introduction 67% in 48-week PEG-IFN plus ribavirin full-dose combination therapy arms, whereas only 37% of patients who received low-dose ribavirin achieved an SVR [7] . As a consequence, ribavirin is included in the clinical development programmes of a multitude of new direct antiviral agents [9] . Ribavirin has been part of the standard of care in patients with CHC for a decade now. Administered together with PEG-IFN, ribavirin is associated with increased early virological response and SVR rates [10] . Recent pharmacokinetic studies suggest that high ribavirin plasma or serum concentrations early during therapy are highly predictive for a subsequent favourable antiviral response [11, 12] . Furthermore, a drop of haemoglobin during antiviral therapy, which is mainly caused by ribavirin-induced haemolysis and is considered one of the main side effects, has been shown to be predictive for SVR in subanalyses of large randomized controlled trials [13] . These data underline the importance of ribavirin exposure and adherence in clinical use [14] .
To tailor optimal anti-HCV treatment strategies that include direct antiviral agents in the future, detailed knowledge of potential synergies with ribavirin co-administration are of particular interest. In the present study, we therefore analysed dose-dependent and time-dependent in vitro kinetics of HCV RNA during treatment with IFN-α and the protease inhibitors boceprevir or telaprevir, all in the presence and absence of ribavirin.
Methods

Compounds
The NS3/4A serine protease inhibitor boceprevir ( formerly SCH503034) was provided by ScheringPlough (Schering-Plough, Kenilworth, NJ, USA). Telaprevir (formerly VX950) was provided by the drugpharm platform of the virgil network funded by the European Commission (European Surveillance Network for Vigilance against Viral Resistance). Human recombinant IFN-α was purchased from Callbiochem (Merck Chemicals Ltd, Nottingham, UK). Ribavirin was purchased from Sigma-Aldrich Chemie Gmbh (Munich, Germany).
HCV subgenomic replicon construct
Huh7 lunet cells harbouring an HCV subgenomic replicon construct (HCV replicon cells) based on the patient-derived consensus isolate, Con1 (HCV 1b subtype), with a combination of three adaptive mutations (E1202G, T1280I within NS3, and K1846T in NS4B) were utilized [15] . In this subgenomic replicon system, the sequences of the structural HCV proteins are replaced by neomycin phosphotransferase as a selectable marker gene. A second internal ribosome entry site element of the encephalomyocarditis virus is inserted to allow for translation of the non-structural proteins NS3-NS5B. HCV replicon cells were grown in Dulbecco's modified minimal essential medium (Life Technologies, Karlsruhe, Germany) containing 10% fetal calf serum, supplemented with 2 mM l-glutamine, non-essential amino acids, 10 mg/ml streptomycin, 25 µg/ml amphotericin B and 10,000 units/ml penicillin.
Ribavirin cytotoxicity assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay was used according to the manufacturer's instructions (Sigma-Aldrich Chemie GmbH) in order to assess ribavirin-induced cytotoxicity in HCV replicon cells. In this assay, yellow MTT is reduced to purple formazan in the mitochondria of living cells. The absorbance of the coloured solution was quantified by a multiwell scanning spectrophotometer at a wavelength of 570-630 nm. Ribavirin was used at several concentrations (50 µM, 100 µM, 200 µM, 500 µM, 1,000 µM and 2,000 µM) over a period of different time points (24 h, 36 h and 48 h, respectively).
HCV replicon inhibition assay
To assess the inhibitory activity of antiviral compounds, the subgenomic HCV replicon RNA was measured by quantitative reverse-transcriptase PCR. Firstly, RNA isolation from HCV replicon cells and RT into cDNA was performed using the Fast Lane Cell cDNA Kit (QIAGEN, Hilden, Germany). Secondly, cDNA was quantified by a real-time PCR assay (StepOnePlus Real-Time PCR system; Applied Biosystems, Weiterstadt, Germany) using specific primers (primer HCV-S, 5′-ACGCAGAAAGCGTCTAGCCAT-3′; primer HCV-AS, 5′-TACTCACCGGTTCCGCAGA-3′) as described before [16] . The fluorogenic probe was labelled with 6-carboxy-fluorescein and tetra-chloro-6-carboxyfluorescein. Human GAPDH mRNA was quantified and used as an endogenous reference. All amplification reactions were performed in duplicates. Cycle conditions were 10 min of initial denaturation at 95°C and 40 cycles of 15 s at 95°C and 1 min at 60°C.
Cultivation studies with boceprevir, IFN-α, ribavirin and telaprevir HCV replicon cells were seeded into 24-well plates at a density of 2×10 4 cells per well and incubated for 12 h. Medium was then aspirated and replaced with complete medium containing a single compound or combinations at the desired concentrations. Plates with compounds were cultivated for a variety of time points and then subjected to HCV subgenomic RNA quantification. All conditions were run at least in triplicate and the relative change of HCV RNA was expressed as mean of the respective wells tested.
For ribavirin monotherapy, concentrations of 10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 200 µM, 500 µM and 1,000 µM were studied at various time points (24 h, 36 h, 48 h and 72 h). Boceprevir was tested at concentrations of 0.15 µM, 0.5 µM, 1 µM, 5 µM and 7.5 µM and various time points (6-48 h). Telaprevir was tested at concentrations of 0.1 µM, 0.35 µM, 0.5 µM, 0.75 µM, 1 µM, 5 µM and 7.5 µM for 6-48 h. Cells were incubated with IFN-α in concentrations of 1 IU, 3 IU, 10 IU, 30 IU and 100 IU for 24 h and 48 h, respectively.
Mathematical modelling of HCV RNA decline and synergy analysis
Single-agent activities Enzyme kinetics obeying the law of mass action result in sigmoid dose-response curves [17] . One common choice is the Hill model, also known as the logistic model [18] . The four-parameter Hill function (Equation 1) was chosen to describe dose-response effects of single agents:
where d is the concentration of the experimental drug, R(d) is the corresponding viral response, R max is the response in absence of any substance, b is the background response observed at infinite drug concentration, IC 50 is the concentration required for obtaining 50% maximal possible inhibition and m is the slope parameter (also called the Hill constant).
Time dependency
HCV replicon cells were exposed to treatment for 6-72 h. The same levels of agent concentrations showed varying inhibitory effects depending on exposure time. In order to avoid time-dependent parameter estimates for 50% maximal inhibitory concentration (IC 50 ) values, we impose the restriction that the IC 50 and the slope parameter remain constant over time but propose to allow for a time-dependent background response. In particular, we examined and incorporated a linear dependency if an improvement of Akaike's information criterion could be observed. In the absence of a mechanistic efficacy model, our approach simplifies the analysis of time-stratified data and allows one to combine the dependencies on the dosing scheme as well as treatment duration.
Parameter estimation Viral response was normalized; that is, the response in absence of any substance equals one. We used a nonlinear mixed-effects model with one random effect to account for the dependencies within concentration series. Approximate 95% CIs on the model parameters are obtained applying a normal approximation to the distribution of (restricted) maximum likelihood estimators.
Combination therapy activities
Bliss independence denotes a widely used null reference model for describing dose-response effects of non-interacting combination therapies [17] [18] [19] [20] . It is based on the assumption that inhibitors act through independent mechanisms. This approach is consistent with the statistical law representing the joint probability of independent events; for example,
in the case of two agents. Experimental effects are categorized into three classes: additivity, synergy and antagonism. Agents are said to be additive when their combination effects coincide with predictions made by the Bliss independence model. In case of synergy, the effect is greater than predicted, whereas it is lower in the case of antagonism. As outlined above, we include time-dependent single-agent activities, where appropriate. Consequently, the resulting Bliss reference model also takes into account potential effects of exposure time. In the following we will refer to it as the modified Bliss model.
Synergy plots
Three-dimensional surface plots illustrate the deviations from theoretical additive combination effects. In the case of non-interacting agents this would result in a horizontal plane at 0% inhibition. Systematic deviations above the zero plane indicate synergy, whereas surface areas below indicate antagonism. The analysis was performed using the authors' own routines written in R (R Foundation for Statistical Computing, Vienna, Austria) and MATLAB ® (MathWorks, Natick, MA, USA) which were adapted to the three-dimensional model by Prichard and Shipman [21] .
Statistical analyses
Deviations from additivity were evaluated using the Wilcoxon test for paired samples and 95% CIs for the median deviation were computed. Tests were two-sided and results with P<0.05 were considered statistically significant.
Results
Monotherapy studies and determination of antiviral activities of ribavirin, IFN-α, telaprevir and boceprevir HCV replicon cells were treated with various concentrations of either ribavirin, IFN-α, telaprevir or boceprevir. All compounds inhibited HCV replication in a time-dependent and dose-dependent manner (Figures 1 and 2) . The IC 50 value after standard 48-h cultivation experiments of ribavirin was 386.16 µM (95% CI 216.25-689.57). Ribavirin is a cytostatic agent and HCV replicon replication proliferation is dependent on the host cell. Results of the MTT cytotoxicity assay showed no cytopathic effect below concentrations of 200 µM ribavirin. These data were in accordance with previous studies [22] . Thus, ribavirin concentrations of 100 µM and 200 µM were chosen for subsequent experiments by taking into account IC 50 and cytotoxicity results. The IC 50 values of IFN-α, telaprevir and boceprevir were 81.67 IU (95% CI 62.75-106.29), 0.81 µM (95% CI 0.75-0.88) and 0.44 µM (95% CI 0.40-0.49), respectively. The IC 50 values served to choose concentrations of the respective compound for the combination studies. Limited access to the compounds in our independent study did not allow additional concentration testing.
Combination therapy studies and modelling of antiviral interactions
To characterize the potential advantage of an in vitro combination of compounds with anti-HCV activity, we co-cultured HCV replicon cells with ribavirin and IFN-α, boceprevir or telaprevir as dual therapy and also as triple antiviral therapy.
Ribavirin and IFN-α
For combination studies, ribavirin was used in concentrations of 100 µM and 200 µM, and IFN in ascending concentrations ranging above and below the IC 50 value (1 IU, 3 IU, 10 IU, 30 IU and 100 IU). HCV RNA was measured after 24 h and 48 h. According to the Bliss independency concept, the combination of these two agents showed slightly synergistic therapeutic effects (95% CI 0.07-0.17, P<0.001), especially in the higher dose range of IFN-α ( Figure 3A ).
Ribavirin and boceprevir or telaprevir
Ribavirin was utilized for combination studies at concentrations of 100 µM and 200 µM. Boceprevir was used in ascending concentrations (0.15 µM, 0.5 µM, 1 µM, 5 µM and 7.5 µM) for combination studies. HCV RNA was measured after 24 h and 48 h at all concentrations. Additionally, experiments with lower boceprevir concentrations (0.15 µM and 0.5 µM; around the boceprevir IC 50 value) were performed at 6 h, 12 h and 36 h. The dual antiviral therapy was additive ( Figure  3B ). Accordingly, telaprevir was co-administered with ribavirin at various concentrations (0.35 µM, 0.75 µM, 1 µM, 5 µM and 7.5 µM) for 24 h and 48 h. Likewise, additional cultivation times were 6 h, 12 h, 24 h and 36 h, for which lower concentrations of telaprevir (0.35 µM and 1 µM; around the telaprevir IC 50 value) were chosen. The modified Bliss independency modelling took into account a potential effect of the different time points, and showed additional therapeutic effects of ribavirin in combination with telaprevir ( Figure 3C ).
IFN-α and direct antiviral agents as combination therapy with and without ribavirin
To further extend the characterization of antiviral interactions, IFN-α was co-cultivated with either boceprevir or telaprevir in the presence or absence of ribavirin ( Figures  4 and 5) . The experiments with concentrations below the IC 50 values for both HCV protease inhibitors showed that either combination therapy led to more pronounced HCV RNA decline as compared with the protease inhibitor monotherapy. The triple therapy containing ribavirin showed the highest antiviral activity for both boceprevir ( Figure 4 ) and telaprevir ( Figure 5 ) in the majority of experiments. The modified Bliss model as described in Methods provided predictions for additive antiviral activity. The statistical analysis suggests that the combination of IFN-α with protease inhibitors in the presence of ribavirin is additive to synergistic. Indeed, the triple therapy of IFN-α, boceprevir and ribavirin showed no significant deviation from additivity. The protease inhibitor telaprevir showed moderately synergistic effects in triple combination (95% CI 0.10-0.42; P<0.01).
Discussion
The guanosine analogue ribavirin has been part of the standard therapy in patients with CHC for more than a decade now [1] . In the near future, novel direct antiviral agents are anticipated to be licensed in many countries, and it is thought this will greatly impact treatment options in CHC. Current development programmes with inhibitors of the HCV NS3/4A serine protease, such as boceprevir and telaprevir, suggest that SVR rates are significantly higher in those patients treated with a triple combination of protease inhibitor, PEG-IFN and ribavirin as compared with the combination of protease inhibitor and PEG-IFN alone [8] . Since the mode of action of ribavirin is still not completely understood, information on the interaction between these different antiviral agents are of special interest for future combination therapies [23] .
In the present study, we used a subgenomic HCV genotype 1b replicon system to study the effect of ribavirin on antiviral activities of IFN-α and the two protease inhibitors boceprevir and telaprevir in vitro. We firstly tested antiviral activities of the different compounds as monotherapies. Ribavirin was mainly used in concentrations below 200 µM that proved not to exert cytotoxicity in our system, or in others [22] . The question arose of whether these relatively high concentrations mirror the situation in patients. In earlier studies, comparable concentrations were found in erythrocytes derived from patients during antiviral therapy, and concentrations above 1,000 µM were associated with a drop in their haemoglobin values [24, 25] . Although hepatocytes and other nucleated body cells may have different exposure to ribavirin than erythrocytes, the concentrations used in the present study were considered adequate and also comparable with existing in vitro studies. Thus, the antiviral activity of ribavirin in vitro was similar to that reported in earlier studies [22] . Likewise, the antiviral activities and IC 50 values of the protease inhibitors boceprevir and telaprevir were comparable with those previously reported [26] .
We then conducted a variety of combination experiments. In addition to the classic determination of inhibitory concentrations of the antiviral agents after 48 h, we included time as an additional parameter into mathematical modelling and established a modified Bliss independency model to study the interaction of antiviral agents. Time may influence the antiviral activity of IFN and ribavirin as those agents are believed to act via indirect rather than direct antiviral mechanisms [27, 28] . Generally, compounds with different modes of actions are thought to produce additive to synergistic activity. A combination of ribavirin and IFN-α led to a synergistic antiviral activity, especially in the higher IFN-α dose range. This observation is in accordance with previous reports [29, 30] and may reflect the situation in patients with CHC.
The dual combination of ribavirin with the α-ketoamide protease inhibitors boceprevir or telaprevir showed additive antiviral activity. In other recent studies, ribavirin has shown additivity with other protease inhibitors such as the macrocyclic protease inhibitor TMC435350 [31] . The precise molecular mechanisms of ribavirin action in patients with CHC are still not fully understood but several hypotheses of direct and indirect mechanisms were proposed (reviewed in [28, 32, 33] ). Ribavirin may act as a weak but direct inhibitor of the HCV-encoded NS5B RNAdependent RNA polymerase. However, if this was the main mechanism of action, possibly more pronounced synergy could have been expected in combination with NS3/4A protease inhibitors. Among indirect mechanisms of action, the error catastrophe hypothesis has been studied by several groups [33] . Thereby, it is assumed that ribavirin acts as an HCV RNA mutagen, promoting the accumulation of mutated genomes with lower viral fitness. Ribavirin may also enhance the expression of IFN-stimulated genes, thereby enhancing the antiviral IFN-α effect [34, 35] . These two, rather indirect, mechanisms would be in agreement with our observation of ribavirin synergy with IFN-α and additive to synergistic antiviral activity together with NS3/4A protease inhibitors. None of the combinations studied here resulted in antagonistic activity. In a previous study in which ribavirin was cultivated with 2′-c-methylcytidine, the active component of the pyrimidine nucleoside analogue valopicitabine, a direct inhibitor of the HCV-encoded NS5B RNA-dependent RNA polymerase, an antagonistic effect was found [17] . These data were in agreement with past data on the combination of ribavirin and zidovudine and were thought to be mediated through the inhibition of intracellular phosphorylation process by ribavirin [36] . However, other recent data on combinations with ribavirin and anti-HCV pyrimidine analogues did rather show additive to synergistic antiviral activity [37] . Inconclusive results may have, among other reasons, a methodological background. Ribavirin doses used in the latter study were lower and possibly less cytotoxic as compared with the study using valopicitabine. However, in our study in which HCV protease inhibitors but no HCV polymerase inhibitors were tested, ribavirin did not diminish the antiviral activity of the other compounds despite relatively high ribavirin concentrations.
Anti-HCV combination therapies not only bear the potential to increase antiviral activity but may also prevent antiviral resistance development in patients with CHC [38] . Some recent in vitro studies showed that the combination of both the cyclophilin inhibitors NIM811 and Debio025 with direct antiviral agents may block or delay the emergence of resistance development [39, 40] . Also, in patients treated with a triple combination of telaprevir, PEG-IFN and ribavirin, virological breakthrough was rarely observed when compared to those who received dual therapy with telaprevir and PEG-IFN alone (1% versus 24%) [8] . Further studies are needed that characterize in detail how ribavirin may prevent or delay emergence of anti-HCV drug resistance.
In summary, our results show that ribavirin provides additive to synergistic antiviral activity together with HCV protease inhibitors and IFN-α in vitro. Our combination studies endorse the prospect that IFN-α and ribavirin may constitute an antiviral backbone for patients with CHC that will receive direct antiviral agents in the near future.
